{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:52:36Z","timestamp":1790794356063,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceutical Company Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00535-019-01572-y","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T20:14:17Z","timestamp":1553717657000},"page":"718-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease"],"prefix":"10.1007","volume":"54","author":[{"given":"Hiroto","family":"Miwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Tango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"1572_CR1","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0889-8553(02)00040-7","volume":"31","author":"GR Locke III","year":"2002","unstructured":"Locke GR III. Natural history of nonerosive reflux disease. Gastroenterol Clin North Am. 2002;31:S59\u201366.","journal-title":"Gastroenterol Clin North Am"},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","volume":"100","author":"KR DeVault","year":"2005","unstructured":"DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190\u2013200.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR3","first-page":"322","volume":"39","author":"L Olbe","year":"1992","unstructured":"Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology. 1992;39:322\u20134.","journal-title":"Hepatogastroenterology"},{"key":"1572_CR4","first-page":"577","volume":"7","author":"JW Freston","year":"1995","unstructured":"Freston JW, Malagelada JR, Petersen H, et al. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 1995;7:577\u201386.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1572_CR5","first-page":"611","volume":"54","author":"W Schwizer","year":"1997","unstructured":"Schwizer W, Fried M. Gastroesophageal reflux. Ther Umsch. 1997;54:611\u20136.","journal-title":"Ther Umsch"},{"key":"1572_CR6","first-page":"30S","volume":"92","author":"JE Richter","year":"1997","unstructured":"Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol. 1997;92:30S\u20135S.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","volume":"93","author":"PL Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797\u2013804.","journal-title":"J Pharmacol Exp Ther"},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","volume":"103","author":"J Dent","year":"2008","unstructured":"Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20\u20136.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"S-738","DOI":"10.1016\/S0016-5085(14)62675-5","volume":"146","author":"E Umegaki","year":"2014","unstructured":"Umegaki E, Iwakiri K, Hiramatsu N, et al. Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10\u00a0mg or 20\u00a0mg once-daily) compared to lansoprazole (15\u00a0mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis. Gastroenterology. 2014;146:S-738.","journal-title":"Gastroenterology"},{"key":"1572_CR11","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. version 5.1.0. 2011. \n                    www.handbook.cochrane.org\n                    \n                  . Accessed 4 June 2018."},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6:e1000097.","journal-title":"PLOS Med"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"1572_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3:111\u201325.","journal-title":"Res Synth Methods"},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/biostatistics\/kxp032","volume":"10","author":"G Lu","year":"2009","unstructured":"Lu G, Ades A. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics. 2009;10:792\u2013805.","journal-title":"Biostatistics"},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0272989X13487604","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33:597\u2013606.","journal-title":"Med Decis Making"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Statist Soc B. 2002;64:583\u2013639.","journal-title":"J R Statist Soc B"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","volume":"111","author":"D Armstrong","year":"1996","unstructured":"Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85\u201392.","journal-title":"Gastroenterology"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/0016-5085(88)90162-X","volume":"95","author":"DJ Hetzel","year":"1988","unstructured":"Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903\u201312.","journal-title":"Gastroenterology"},{"key":"1572_CR20","first-page":"1758","volume":"91","author":"SJ Sontag","year":"1996","unstructured":"Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol. 1996;91:1758\u201365.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1111\/j.1572-0241.2000.03179.x","volume":"95","author":"A Caos","year":"2000","unstructured":"Caos A, Moskovitz M, Dayal Y, et al. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. Am J Gastroenterol. 2000;95:3081\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/00042737-200012080-00008","volume":"12","author":"C Birbara","year":"2000","unstructured":"Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol. 2000;12:889\u201397.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2036.2005.02555.x","volume":"22","author":"A Caos","year":"2005","unstructured":"Caos A, Breiter J, Perdomo C, et al. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20\u00a0mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22:193\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3109\/00365529509101589","volume":"30","author":"LS Laursen","year":"1995","unstructured":"Laursen LS, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol. 1995;30:839\u201346.","journal-title":"Scand J Gastroenterol"},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2036.2003.01464.x","volume":"17","author":"K Lauritsen","year":"2003","unstructured":"Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20\u00a0mg and lansoprazole 15\u00a0mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther. 2003;17:333\u201341.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1365-2036.2001.01024.x","volume":"15","author":"NB Vakil","year":"2001","unstructured":"Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927\u201335.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","volume":"96","author":"DA Johnson","year":"2001","unstructured":"Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6\u00a0months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27\u201334.","journal-title":"Am J Gastroenterol"},{"key":"1572_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","volume":"4","author":"KR Devault","year":"2006","unstructured":"Devault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1572_CR29","first-page":"742","volume":"45","author":"B Annibale","year":"1998","unstructured":"Annibale B, Franceschi M, Fusillo M, et al. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepatogastroenterology. 1998;45:742\u201351.","journal-title":"Hepatogastroenterology"},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","volume":"29","author":"DC Metz","year":"2009","unstructured":"Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:742\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/gut.43.4.458","volume":"43","author":"KD Bardhan","year":"1998","unstructured":"Bardhan KD, Cherian P, Vaishnavi A, et al. Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10\u00a0mg or placebo. Gut. 1998;43:458\u201364.","journal-title":"Gut"},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1365-2036.1996.14156000.x","volume":"10","author":"AL Gough","year":"1996","unstructured":"Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2036.2004.02121.x","volume":"20","author":"JE Richter","year":"2004","unstructured":"Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20:567\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1365-2036.2003.01410.x","volume":"17","author":"DC Metz","year":"2003","unstructured":"Metz DC, Bochenek WJ, Pantoprazole US GERD Study Group. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther. 2003;17:155\u201364.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1023\/A:1005548318996","volume":"45","author":"B Thjodleifsson","year":"2000","unstructured":"Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45:845\u201353.","journal-title":"Dig Dis Sci"},{"key":"1572_CR36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10620-008-0466-9","volume":"54","author":"DA Peura","year":"2009","unstructured":"Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci. 2009;54:955\u201363.","journal-title":"Dig Dis Sci"},{"key":"1572_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7326\/0003-4819-124-10-199605150-00001","volume":"124","author":"M Robinson","year":"1996","unstructured":"Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:859\u201367.","journal-title":"Ann Intern Med"},{"key":"1572_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/gut.36.4.492","volume":"36","author":"CM Bate","year":"1995","unstructured":"Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10\u00a0mg or 20\u00a0mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut. 1995;36:492\u20138.","journal-title":"Gut"},{"key":"1572_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0016-5085(94)90531-2","volume":"107","author":"B Hallerback","year":"1994","unstructured":"Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology. 1994;107:1305\u201311.","journal-title":"Gastroenterology"},{"key":"1572_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2036.1997.144320000.x","volume":"11","author":"JG Hatlebakk","year":"1997","unstructured":"Hatlebakk JG, Berstad A. Lansoprazole 15 and 30\u00a0mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther. 1997;11:365\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR41","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","volume":"333","author":"S Vigneri","year":"1995","unstructured":"Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106\u201310.","journal-title":"N Engl J Med"},{"key":"1572_CR42","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Lansoprazole OD tablets 15\u00a0mg \u201cTOWA\u201d\/OD tablets 30\u00a0mg \u201cTOWA\u201d. Accessed 18 Jan 2019. 2017."},{"key":"1572_CR43","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Omeprazole 10\u00a0mg\/20\u00a0mg capsules. Accessed 18 Jan 2019. 2017."},{"key":"1572_CR44","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Esomeprazole 10\u00a0mg\/20\u00a0mg capsules. Accessed 18 Jan 2019. 2018."},{"key":"1572_CR45","doi-asserted-by":"publisher","first-page":"e8120","DOI":"10.1097\/MD.0000000000008120","volume":"96","author":"MJ Li","year":"2017","unstructured":"Li MJ, Li Q, Sun M, et al. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis. Med (Baltim). 2017;96:e8120.","journal-title":"Med (Baltim)"},{"key":"1572_CR46","doi-asserted-by":"publisher","first-page":"41021","DOI":"10.1038\/srep41021","volume":"7","author":"C Zhang","year":"2017","unstructured":"Zhang C, Kwong JS, Yuan RX, et al. Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD: network meta-analysis and GRADE system. Sci Rep. 2017;7:41021.","journal-title":"Sci Rep"},{"key":"1572_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12328-008-0039-7","volume":"1","author":"H Miwa","year":"2008","unstructured":"Miwa H, Oshima T, Tomita T, et al. Gastro-esophageal reflux disease: the recent trend in Japan. Clin J Gastroenterol. 2008;1:133\u20138.","journal-title":"Clin J Gastroenterol"},{"key":"1572_CR48","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"Y Fujiwara","year":"2009","unstructured":"Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518\u201334.","journal-title":"J Gastroenterol"},{"key":"1572_CR49","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s00535-011-0429-3","volume":"46","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Adachi K, Hongo M, et al. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. J Gastroenterol. 2011;46:1092\u2013103.","journal-title":"J Gastroenterol"},{"key":"1572_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/10773525.2016.1235675","volume":"22","author":"SH Jang","year":"2016","unstructured":"Jang SH, Ryu HS, Choi SC, et al. Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea. Int J Occup Environ Health. 2016;22:315\u201320.","journal-title":"Int J Occup Environ Health"},{"key":"1572_CR51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048\u201359.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"1572_CR52","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1111\/j.1440-1746.2005.04167.x","volume":"20","author":"PW Lim","year":"2005","unstructured":"Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs\u2013focus on rabeprazole. J Gastroenterol Hepatol. 2005;20(Suppl):S22\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1572_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/gut.35.5.590","volume":"35","author":"J Dent","year":"1994","unstructured":"Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994;35:590\u20138.","journal-title":"Gut"},{"key":"1572_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3109\/00365529109025038","volume":"26","author":"L Lundell","year":"1991","unstructured":"Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991;26:248\u201356.","journal-title":"Scand J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01572-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01572-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01572-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:04:27Z","timestamp":1585181067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01572-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01572-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hiroto Miwa has received research funding from Takeda Pharmaceutical Company, Ltd., Otsuka Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., and Eisai Co., Ltd., and honorarium from Takeda Pharmaceutical Company, Ltd., Otsuka Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., and AstraZeneca K. K.; Ataru Igarashi has received research grants from Pfizer Japan Inc., CSL Behring Japan Inc., Gilead Science K. K., and Fuji Film K. K., consulting fees from Novartis Pharma K. K., AbbVie GK, Milliman, Sony Inc., and Eli Lilly Japan K. K., and lecture fees from Chugai Pharmaceutical Company, Ltd., CRECON Research and Consulting Inc., Terumo Corporation, Bristol-Myers Squibb K. K., and Creativ-Ceutical K. K.; Toshiro Tango has received consulting fees from Takeda Pharmaceutical Company, Ltd., AbbVie GK, Ajinomoto Pharma, and Lion Corporation; Akihito Uda and Hisato Deguchi are employees of Takeda Pharmaceutical Company, Ltd.; Lida Teng has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}